Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB

Rhea-AI Summary

Agenus (Nasdaq: AGEN), a clinical-stage immuno-oncology company, has announced a conference call scheduled for March 13, 2023, at 8:30 a.m. ET. The purpose of the call is to discuss its minority cash holdings at Silicon Valley Bank (SVB). Interested participants can dial in using specific numbers provided in the release. Agenus focuses on developing therapies to enhance the immune system's ability to combat cancer and infections, leveraging its broad range of antibody therapeutics, cell therapies, and adjuvants. The company is headquartered in Lexington, Massachusetts.

Positive

• Agenus is holding a conference call to discuss minority cash holdings, indicating transparency with investors.
• The company operates in the growing immuno-oncology sector, which has significant potential for future revenue growth.

Negative

• The need to address cash holdings at Silicon Valley Bank may raise concerns about liquidity or financial stability.

Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET

LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it will hold a conference call to provide detail and to answer any questions regarding its minority cash holdings at Silicon Valley Bank (SVB) at 8:30 a.m. ET on Monday, March 13th.

Conference Call
Dial-in numbers: (646) 307-1963 (US) or (800) 715-9871 (International)
Conference ID: 9540056.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact
Agenus Inc.
Zack Armen
Head of Investor Relations
917-362-1370
zack.armen@agenusbio.com

FAQ

When is the Agenus conference call scheduled?

The Agenus conference call is scheduled for March 13, 2023, at 8:30 a.m. ET.

What is the purpose of the Agenus conference call?

The purpose of the conference call is to provide details about Agenus's minority cash holdings at Silicon Valley Bank.

How can I participate in the Agenus conference call?

You can participate by dialing (646) 307-1963 for the US or (800) 715-9871 for international calls, using the conference ID 9540056.

What does Agenus focus on?

Agenus focuses on developing therapies aimed at activating the immune system to fight cancer and infections.

Where is Agenus headquartered?

Agenus is headquartered in Lexington, Massachusetts.